TrialCancer immunology, immunotherapy : CII2016

Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.

Robert A Fenstermaker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.